Compositions, Methods and Kits for Diagnosis of Lung Cancer
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 6 of these applications claim priority to application 61/578,712, filed Dec 21, 2011. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,304,137 | Compositions, Methods and Kits for Diagnosis of Lung Cancer In force · High confidence | Biodesix, Inc. | In force | High confidence | ||
| US 9,588,127 | Compositions, Methods and Kits for Diagnosis of Lung Cancer In force · High confidence | Biodesix, Inc. | In force | High confidence | ||
| US 10,338,074 | Compositions, Methods and Kits for Diagnosis of Lung Cancer In force · High confidence | Biodesix, Inc. | In force | High confidence | ||
| US 11,913,957 | Compositions, Methods and Kits for Diagnosis of Lung Cancer In force · High confidence | Biodesix, Inc. | In force | High confidence | ||
| US 12,247,980 | Compositions, Methods and Kits for Diagnosis of Lung Cancer In force · High confidence | Biodesix, Inc. | In force | High confidence | ||
| US 9,201,044 | Compositions, Methods and Kits for Diagnosis of Lung Cancer In force · High confidence | Biodesix, Inc. | In force | High confidence |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.